Evidence map›Paper›PMID 32435751›Full record

ArticleTherapeutic advances in vaccines and immunotherapy2020

Amanda Izeli Portilho, Gabriela Trzewikoswki de Lima, Elizabeth De Gaspari

Open access · diamondAbstract read
In one paragraph

Article in Therapeutic advances in vaccines and immunotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. A Rare Cause of a Rare Disorder:Case reports in critical care · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Amanda Izeli PortilhoDepartament of Immunology, Adolfo Lutz Institute, São Paulo, Brazil Post-Graduate Program Interunity in Biotechnology, Biomedical Sciences Institute, São Paulo University, São Paulo, Brazil.
Gabriela Trzewikoswki de LimaDepartament of Immunology, Adolfo Lutz Institute, São Paulo, Brazil Post-Graduate Program Interunity in Biotechnology, Biomedical Sciences Institute, São Paulo University, São Paulo, Brazil.
Elizabeth De GaspariDepartament of Immunology, Adolfo Lutz Institute, Dr Arnaldo Avenue 355, 11 floor, São Paulo, SP 01246-902, Brazil.ORCID https://orcid.org/0000-0001-8332-2248
Instituto Adolfo Lutz · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsThe characterization of Lipopolysaccharide (LPS) and type IV pili in 19 meningococci strains of serogroup B, 21 of serogroup C, 45 of serogroup W and 28 of serogroup Y, isolated in Brazil between 2011 and 2017, was conducted using the Enzyme-linked Immunosorbent Assay (Dot- ELISA) technique and monoclonal antibodies.

resultsWe would like to emphasize the importance of characterizing relevant antigens, such as pili and LPS, the use of monoclonal antibodies to support it, and how such studies improve vaccine development and monitoring. Most of the strains studied presented L3,7,9 LPS and type IV pili; both antigens are associated with the capacity to cause invasive disease.

conclusionDue to the impact of meningococcal disease, it is important to maintain and improve vaccine studies. Epitopes characterization provides data about the virulence of circulating strains. The use of monoclonal antibodies and serological techniques are relevant and support vaccine development.

Indexed as

invasive meningococcal diseaseLPSNeisseria meningitidispiliserotyping

Identifiers

PMID32435751
PMCPMC7225800
OpenAlexW3021468855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.